{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-23-000119","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.217054+00:00","generated_at":"2026-06-07T14:57:56.664274+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Autolus obe-cel FELIX pooled analysis: 78% CR/CRi, 12-mo EFS 50%, low immunotoxicity; BLA filed for r/r B-ALL","bullets":["Pooled FELIX Phase Ib/II (n=127): CR/CRi rate 78%; grade ≥3 CRS 2%, ICANS 7%; median follow-up 16.6 months.","Patients with <5% BM blasts at lymphodepletion: 12-mo EFS 65%, no grade ≥3 CRS or ICANS (n=36).","Pooled ALLCAR19/FELIX Ib (n=36) in r/r B-ALL: 81% remission rate; 41% in ongoing CR at median >3 years follow-up without transplant.","AUTO8 (BCMA/CD19 dual CAR) MCARTY Phase I (n=11): 100% ORR, 7 CR/sCR, no grade ≥3 CRS/ICANS; trial enrolling.","BLA for obe-cel in relapsed/refractory adult B-ALL submitted to FDA; ASH data support regulatory filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-23-000119","json":"https://secwatch.observer/filing/0001730463-23-000119.json","markdown":"https://secwatch.observer/filing/0001730463-23-000119.md","text":"https://secwatch.observer/filing/0001730463-23-000119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046323000119/0001730463-23-000119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046323000119/autl-20231209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:57:56.664274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}